LDS/Medical Tests/Fragile X, FMR1 Gene Mutation Analysis

Fragile X, FMR1 Gene Mutation Analysis

Fragile X syndrome is an X-linked disorder occurring at a frequency of 1/4000 and 1/6000 in males and females, respectively. Expression of Fragile X is variable and the syndrome is thought to be the second most common cause of mental retardation. Fragile X Syndrome is the result of an unstable expansion of the CGG-repeat region (FRAXA) in the FMR-1 gene located on the X chromosome. A similar mutation (FRAXE) is located on the neighboring FMR-2 gene and involves large expansions of CCG repeats. The disease phenotype of FRAXE is less severe and less prevalent than Fragile X Syndrome. FRAXE mutations are indistinguishable from FRAXA using cytogenetic karyotyping, but can be separated using molecular analysis.

The Normal genotype of FRAXA in the general population contains 29-30 repeats. Transmission of this type shows little to no change across generations. Premature carriers are individuals that have expanded repeat regions with 50-200 repeats. The lower range of repeat units for premature carriers is undetermined; therefore, an indeterminate category is established at 45-55 repeats. Indeterminate alleles have functioning genes, but result in an increased risk of Fragile X in descendants. Phenotypically, premature carriers do not exhibit features of Fragile X but are at risk for abnormal features including premature ovarian failure (POF) and Fragile X tremor/ataxia syndrome (FXTAS).

Full mutations (Fragile X) are defined as >200-1000’s of repeat units and are associated with methylation of the promoter region of the FMR-1, which often results in shutdown of the gene expression or no protein production leading to Fragile X Syndrome. In addition to mental retardation, phenotypic changes associated with Fragile X syndrome or full mutations include large ears, a long and narrow face, and moderately increased head circumference. Macroorchidism is also commonly observed in young affected males. Other common features include hyperactivity, attention deficit disorder, and autism.

Because this is an X-link disorder, the genetic transmission varies between males and females. For example, all mothers of affected sons are carriers of either a full mutation or a premutation of the FMR1 allele. When transmitted by an unaffected carrier father, premutation FMR1 alleles usually don’t change to full mutation and don’t result in the affected phenotype. In contrast, premutation alleles will change to a full mutation if transmitted by an unaffected carrier mother. Therefore, carrier mothers that carry premutated FMR1 alleles are at risk of having an affected offspring, but not paternal carriers. Furthermore, all sons but only half of daughters with the full mutations will develop disease. Regardless of phenotype, all female carriers of the full mutation are at 100% risk of having an affected son and about 50% of having an affected daughter.

Screening for a carrier status and or diagnosis of Fragile X syndrome requires a DNA test that detects expansion of CGG trinucleotide repeats and aberrant methylation of the promoter region. Screening and diagnosis can be performed by molecular methods such as Southern blot analysis and PCR.

  • Carrier status for individuals with a family history of Fragile X syndrome
  • Prenatal testing when there is a positive family history
  • Diagnosis of Fragile X syndrome, FXTAS, POF caused by the unstable expansion of the FMR1 gene
  • No mutation (5-44 CGG repeats): Rules out diagnosis of Fragile X syndrome or premature carrier status
  • Indeterminate or grey-zone (45-54 CGG repeats): FMR-1 gene is functional, but a CGG repeat number of this size may lead to further expansion and, thus, an increased risk of Fragile X syndrome in descendants
  • Premutation (55-200 CGG repeats): establishes individual as a carrier of Fragile X syndrome
  • Full mutation (>200 CGG repeats): establishes diagnosis of Fragile X syndrome in males and in females with clinical signs of the disorder. Establishes carrier status in females

Normal alleles: 5-44 CGG repeats

Intermediate (grey-zone) alleles: 45-54 CGG repeats

Premutation alleles: 55-200 CGG repeats

Full mutation alleles >200 CGG repeats



 

 

Southern Blot analysis, Polymerase Chain Reaction (PCR), Sanger sequencing, Next Generation Sequencing. 

 

Whole blood EDTA (Lavander), Heparin (Green) or ACD A or B (Yellow). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Constitutional chromosomal analysis by cytogenetics, CK, CK-MB, LDH.

1-2 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login